In conclusion, this study revealed that CRM1 is a predictive biomarker for poor overall survival in laryngeal cancer patients, and that the evaluation of the clinical pTNM staging system of the tumor and CRM1 expression together may provide additional prognostic information. The gene discussed is XPO1; the disease is neoplasm.